AGIO Agios Pharmaceuticals
- 45.030
- +0.120+0.27%
- 45.030
- 0.0000.00%
Agios Pharmaceuticals News
Agios Pharmaceuticals Insider Sold Shares Worth $474,140, According to a Recent SEC Filing
Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?
Express News | Agios Pharmaceuticals Shares Are Trading Higher After the Company Announced It Will Receive $1.1 Billion in Milestone Payments
Agios Pharmaceuticals' Shares Rise Ahead of $1.1B in Milestone Payments
Express News | Agios Pharmaceuticals Inc - to Prepare for Potential Pyrukynd Launches in 2025 and 2026
Express News | Agios Pharmaceuticals Inc - Expects $905 Million Payment From Royalty Pharma in Q3 2024
Express News | Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results
Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
Agios Pharmaceuticals Is Maintained at Outperform by RBC Capital
Express News | RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55
Agios Pharmaceuticals Analyst Ratings
Agios' Pyrukynd Misses Primary Endpoint in Phase 3 Pediatric Rare Blood Disorder Trial
Express News | Agios Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $52 From $49
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $55
Express News | Agios Pharmaceuticals Inc : RBC Raises Target Price to $55 From $53
Express News | Agios Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $60 From $61
Earnings Call: Agios Reports Positive Phase 3 Results, Preps for Drug Launches
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Analysis
Price Target
No Data
